Statistical analysis
The immunological non-inferiority of NmCV-5 compared to MenACWY-D was assessed based on achieving the criteria set for either of the two primary endpoints. A prospective alpha allocation scheme was employed for multiplicity adjustment. One-sided significance levels of 0.02 and 0.0051 were applied to non-inferiority testing for seroresponse rates with a margin of −10% and GMTs with a margin of 0.5, respectively. The difference in the percentages of participants with serogroup-specific seroresponse between NmCV-5 and MenACWY-D (seroresponseThe sample size and power calculations are provided in the 